样式: 排序: IF: - GO 导出 标记为已读
-
Physical activity and sedentary behavior as treatable traits for clinical control in moderate-to-severe asthma J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-15 Fabiano F. de Lima PT PhD, Juliana M.B. dos Santos PE PhD, Adriana C. Lunardi PT PhD, Joice M. de Oliveira PT PhD, Patrícia D. Freitas PT PhD, Fabiana S. Kim PT MSc, Rosana Câmara Agondi MD PhD, Regina M. Carvalho-Pinto MD PhD, Karina C. Furlanetto PT PhD, Celso R.F. Carvalho PT PhD.
Physical activity and sedentary behavior are treatable traits that may impact asthma control in distinct manners, but this impact remains poorly understood. To evaluate the influence of physical activity and sedentary behavior on clinical control in adults with moderate-to-severe asthma. This cross-sectional multicentric study included 426 individuals with moderate-to-severe asthma. Assessments included
-
Differences in Characteristics Between Patients Who Met or Partly Met the Diagnostic Criteria for Food Protein-Induced Enterocolitis Syndrome (FPIES) J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-14 Daisuke Hayashi MD, Koichi Yoshida MD PhD, Masayuki Akashi MD PhD, Naoki Kajita MD, Chiho Tatsumoto MD, Tomo Ishii MD, Yumi Koike MD, Kenta Horimukai MD PhD, Misako Kinoshita MD, Yuko Hamahata MD, Hajime Nishimoto MD PhD, Tetsuhiro Sakihara MD, Yohei Arakaki MD, Monami Hara MD, Emiko Noguchi MD PhD, Hideaki Morita MD PhD
Some patients with food protein-induced enterocolitis (FPIES)-like allergy do not completely fulfill the diagnostic criteria of the international consensus guideline for FPIES. However, it is unclear whether such FPIES-like patients represent a completely different population from FPIES or not. This study aimed to clarify the differences in characteristics between the FPIES patients who fully met the
-
Food aversion and anxiety represent primary patient barriers to food oral immunotherapy J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-14 Jordan Trevisonno MD, Carina Venter PhD RD, Kaci Pickett-Nairne MS, Philippe Bégin MD PhD, Scott B. Cameron MD PhD, Edmond S. Chan MD FRCPC, Victoria E. Cook MD MSc, Jeffrey M. Factor MD, Marion Groetch MS RDN, Mariam A. Hanna MD, Douglas H. Jones MD, Richard L. Wasserman MD PhD, Douglas Paul Mack MD MSc
While oral immunotherapy (OIT) for food allergy is a reasonable treatment option, barriers to this procedure’s implementation have not been extensively evaluated from a patient perspective We evaluated the barriers patients face during OIT administration, including anxiety and taste aversion, and evaluated the role of healthcare professionals, especially dietitians A survey in Canada and the US involved
-
Administration of an alternative iodinated contrast media in confirmed severe delayed hypersensitivity reactions J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-13 Angèle Soria MD PhD, Claire Bernier MD, Brigitte Milpied MD, Haudrey Assier MD, Florence Castelain MD, Emmanuelle Amsler MD, Annick Barbaud MD PhD, FISARD group
-
Unraveling Cephalosporin-Associated Anaphylaxis: A Comprehensive Analysis Using FDA Adverse Event Reporting System (FAERS) Data J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-12 Divya Shah MD, Christine Rukasin MD, Cong Wang BS, Elizabeth Phillips MD, Cosby Stone MD
-
Efficacy of various dosing frequencies of dupilumab in patients with aspirin-exacerbated respiratory disease J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-12 Alyson N. Brown BA, Tanya M. Laidlaw MD, Kathleen M. Buchheit MD, Jillian C. Bensko PA-C, Rose C. Corcoran BA, Laura B. Bailey BA.
-
Detecting Changes in Mast Cell Numbers vs. Activation in Human Disease: A Roadblock for Current Biomarkers? J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-11 Cem Akin MD PhD, Frank Siebenhaar MD, Joshua B. Wechsler MD, Bradford A. Youngblood PhD, Marcus Maurer MD
The pathophysiology of mast cell (MC)-driven disorders is diverse, ranging from localized reactions to systemic disorders caused by abnormal accumulation and activation in multi-organ systems. Prompt and accurate diagnosis is critically important, both for informing treatment and objective assessment of treatment outcomes. As new therapeutics are being developed to deplete MCs or silence them (e.g
-
Nonallergic Rhinopathy: A Comprehensive Review of Classification, Diagnosis, and Treatment J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-11 Fuad M. Baroody M.D., Philippe Gevaert M.D. Ph.D., Peter K. Smith M.D., Navid Ziaie M.D., Jonathan A. Bernstein M.D.
Chronic nonallergic rhinitis (NAR) syndromes encompasses various conditions, of which vasomotor (VMR) rhinitis is the most common form representing approximately 80% of patients also referred to as nonallergic rhinopathy, nasal hyperreactivity, neurogenic rhinitis or idiopathic rhinitis. Expert panels have recommended replacing VMR terminology as it is more descriptive of this condition that is characterized
-
CME CLINICAL COMMENTARY REVIEW: Patient Centered Practice Guidelines: GRADEing Evidence to Incorporate Certainty, Balance Between Benefits and Harms, Equity, Feasibility, and Cost-Effectiveness J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-11 Ellen Stephen MD, Alexandra E. Conway BA, Christopher D. Codispoti MD PhD, Elissa Abrams, Jay A. Lieberman MD, Dennis Ledford MD, Thanai Pongdee MD, Marcus Shaker MD MS
The practice of medicine in recent years has emphasized the use of evidence-based clinical guidelines to help inform treatment decisions. Since its development in 2004, the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach has offered a systematic process for reviewing and summarizing the certainty of evidence found in the medical literature regarding various treatment
-
Recurrent Localized Erythema Scarlatiniforme Desquamativum Recidivans Induced by Iodinated Contrast Media J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-10 Leyla Barakat MD, Marie Lagreula MD, Raphaël Zermati, Félix Laborier MD, Anca Mirela Chiriac MD PhD, Catherine Neukirch MD
-
Pharmacoequity & Biologics In The Allergy Clinic: Providing The Right Care, At The Right Time, Every time, To Everyone J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Alexandra E. Conway BA, Jay Lieberman MD, Christopher D. Codispoti MD PhD, Mahboobeh Mahdavinia MD PhD, Aikaterini Anagnostou MD PhD, Karen S. Hsu Blatman MD, David M. Lang MD, John Oppenheimer MD, Giselle S. Mosnaim MD MS, Don Bukstein MD, Marcus Shaker MD MS
Pharmacoequity refers to equity in access to pharmacotherapy for all patients and is an especially large barrier to biologic agents in patients with allergic diseases. Value-based care models can prompt clinicians to address social determinants of health, thereby promoting pharmacoequity. Pharmacoequity is influenced by numerous factors including socioeconomic status (SES), which may be mediated through
-
Upper respiratory tract infections have minimal impact on neffy’s pharmacokinetics or pharmacodynamics. J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 John Oppenheimer MD, Thomas Casale MD, Carlos A. Camargo Jr. MD DrPH, David Fleischer MD, David Bernstein MD, Richard Lowenthal MS, Sarina Tanimoto MD PhD
-
NOVEOS™ and ImmunoCAP™ have similar performances for diagnosing food allergies. J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Benjamin Trouche-Estival PharmD, Joana Vitte MD PhD, Audrey Martin-Blondel MD, Marine Michelet MD, Vianney Gruzelle MD, Alain Didier MD PhD, Laurent Guilleminault MD PhD, Claire Mailhol MD, Silvia Martinez Rivera PharmD, Anaïs De Lima Correia AAS, Camille Taurus AAS, Antoine Blancher MD PhD, Julien Goret PharmD PhD, Caroline Klingebiel MD, Pol André Apoil MD PhD
The clinical interest of newly available platforms for specific IgE measurement must be evaluated. However, data are lacking for NOVEOS™ (Hycor), in particular for food allergens. We compared technical and clinical performance of two platforms (ImmunoCAP™ and NOVEOS™) for the measurement of specific IgE to 10 food allergens. Sera from 289 clinically-characterized patients were tested for IgE specific
-
Dilemma of Mast Cell Activation Syndrome: Overdiagnosed or Underdiagnosed? J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 C, e, m, , A, k, i, n, , M, D, , P, h, D
-
Reply to “Challenging dated conceptions to advocate for evidence-informed care in multiple chemical sensitivity” J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Karen Binkley MD FRCPC, Herman Staudenmayer PhD
-
Challenging dated conceptions to advocate for evidence-informed care in multiple chemical sensitivity J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 John Molot MD FCFP, Farah Tabassum MD FCFP, Domenica Tambasco MD FCFP MSc, Moira Sarah Selke MB MCh BAO CCFP, Kathleen Kerr MD Dip Env Health, Riina Bray BASc MSc MD FCFP MHSc, Jennifer Swales MBBS CCFP, L. Christine Oliver MD MPH MSc, Jonathan Fox MD CCFP FCFP
-
Allergic Rash Mimickers J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Dayne H. Voelker MD, Kelly M. Maples MD
-
Reply to “Both quality of life and exacerbation are important outcomes of work-related asthma” J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Eva Suarthana MD MSc PhD, Nicole Le Moual PhD, Paul K. Henneberger MPH ScD, Hormoz Nassiri Kigloo MD, Olivier Vandenplas MD PhD
-
Both quality of life and exacerbation are important outcomes of work-related asthma J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Jong Geol Jang MD, Hyun Lee MD PhD, Kyung Hoon Min MD PhD, Sang-Heon Kim MD PhD, Ho Joo Yoon MD PhD, Ji-Yong Moon MD PhD
-
Complexity and Diversity of Food Allergy Requires Individualized Care J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Julie Wang MD, Robert A. Wood MD
-
Managing CPAP Rhinitis J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Jalal Moolji MD, Adil Adatia MD
-
The Sea of Change in Fish Allergy: Navigating Toward a Personalized Approach J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Sultan Majid DO, Punita Ponda MD
-
Reply to “The use of basophil activation tests (BATs) in the diagnosis of penicillin allergy” J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Miriam R. Bennett MBBS, Alexander G. Mathioudakis PhD MBChB, Chiara Tontini MBBS PGDip Allergy/Clinical Immunology, Angela Simpson MD
-
The use of basophil activation tests (BATs) in the diagnosis of penicillin allergy J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Didier G. Ebo MD PhD, Vito Sabato MD PhD, Christel Mertens MLT, Athina L. Van Gasse MD PhD
-
Reply to “Does atopic dermatitis confer a clinically meaningful risk of cardiovascular disease?” J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Zelma C. Chiesa Fuxench MD MSCE, Joy Wan MD MSCE, Joel M. Gelfand MD MSCE
-
Does atopic dermatitis confer a clinically meaningful risk of cardiovascular disease? J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Natalia V. Chalupczak BS, Jonathan D. Greenzaid BS, Steven R. Feldman MD
-
Intense allergic reactions to personalized oral immunotherapy treatments for food allergies at home J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Jarrod Van Loon BS, Patrick Wu BS, Su-Boon Yong MD PhD
-
Reply to “Intense allergic reactions to personalized oral immunotherapy treatments for food allergies at home” J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Liat Nachshon MD, Naama Schwartz PhD, Michael B. Levy MD, Michael Goldberg MD PhD, Naama Epstein-Rigbi MD, Yitzhak Katz MD, Arnon Elizur MD
-
Regulatory and Insurance Challenges Must Be Overcome in the United States to Meet Global Standards for Asthma Management J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-06 Nonie S. Arora MD MBA, Sherry Zhou MD MSc, Alan P. Baptist MD MPH
-
Airway Diseases Related to the Use of Cleaning Agents in Occupational Settings J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-03-02 Hussein H. Mwanga MD MMed PhD, Orianne Dumas PhD, Nicolas Migueres MD, Nicole Le Moual PhD, Mohamed F. Jeebhay MBChB MPH PhD
Exposure to disinfectants and cleaning products (DCPs) is now a well-established risk factor for work-related asthma (WRA). However, questions remain on the specific causal agents and pathophysiological mechanisms. Few studies have also reported an association between DCPs and rhinitis or chronic obstructive pulmonary disease. This review discusses the recent evidence pertaining to airway diseases
-
Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-29 Ayobami Akenroye MBChB MPH PhD, James Marshall MPH, Andrew L. Simon ScM, Christian Hague MPH, Rebecca Costa MS, Aziza Jamal-Allial PhD, Cheryl N. McMahill-Walraven PhD, Katie Haffenreffer BS, Amy Han MPH, Ann Chen Wu MD MPH
Evidence on the comparative effectiveness of respiratory biologics remains sparse. We sought to evaluate the comparative effectiveness of omalizumab, mepolizumab, benralizumab, and dupilumab in a matched retrospective cohort of patients with asthma. We identified patients with asthma aged ≥18 years who were incident users of these biologics between November 1, 2018, and June 30, 2023, in administrative
-
Characterization of alpha-gal syndrome and sensitization on Eastern Long Island J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-28 Ari Heffes-Doon MD, Erin McGintee MD, Meredith Akerman MS, Erin Banta MD
-
Association between the presence of food allergy and asthma outcomes in allergic asthmatic adults: A case-control study J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-28 Diane Pelletier de Chambure MD, Stéphanie Fry MD, Cécile Chenivesse MD PhD
-
Consequences of NSAID allergy on pain control options for patients with aspirin-exacerbated respiratory disease J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-28 Laura B. Bailey BA, Alyson Brown BA, Rose Corcoran BA, Jillian C. Bensko PA-C, Kathleen Buchheit MD, Tanya M. Laidlaw MD
-
Implementing Food Oral Immunotherapy Into Clinical Practice: Quality and Safety Perspectives From a US Academic Center J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-28 Andrew Winslow MD, Christa Mills MSN RN CNL CPN, Justin Schwartz MD PhD, Amal Assa’ad MD
Oral immunotherapy (OIT) is an accessible procedure for practicing allergy/immunology providers, yet rigorous safety standards are limited in the clinical setting. By exploring the transition from research to clinical practice OIT, we review relevant safety considerations necessary for the clinical provider. We offer a perspective on clinical benefits and considerations at the individual, collaboration
-
Non–IgE-Mediated Immediate Drug-Induced Hypersensitivity Reactions J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-28 Santiago Alvarez-Arango MD, Mukesh Kumar PhD, Timothy G. Chow MD, Vito Sabato MD PhD
Immediate drug-induced hypersensitivity reactions (IDHSRs) have conventionally been attributed to an immunoglobulin E (IgE)–mediated mechanism. Nevertheless, it has now been acknowledged that IDHSRs can also occur independently of IgE involvement. Non–IgE-mediated IDHSRs encompass the activation of effector cells, both mast cell–dependent and –independent and the initiation of inflammatory pathways
-
High Degree of Desensitization After 1 Year of Early-Life Peanut Oral Immunotherapy: Small Children Oral Immunotherapy Randomized Controlled Trial J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-28 Carina Uhl MD, Susanna Klevebro MD PhD, Eva Sverremark-Ekström PhD, Sandra G. Tedner MD PhD, Josef Brandström MD PhD, Chrystalleni Papageorgiou MD, Erik Melén MD PhD, Jon R. Konradsen MD PhD, Caroline Nilsson MD PhD, Anna Asarnoj MD PhD
The prevalence of peanut allergy is about 2% and mostly lifelong. Studies of oral immunotherapy (OIT) with peanut (the daily oral intake of an initially low and then increasing dose of peanut) often show problematic side effects, but there are indications of better safety and effect in younger children compared with older children and adults. To determine the safety and effectiveness of peanut OIT
-
Safety of sting challenge test in patients with clonal mast cell diseases J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-27 Arantza Vega-Castro MD PhD, Gaspar Dalmau-Duch MD PhD, Lluís Marquès MD, David González-de-Olano MD PhD, Berta Ruiz-León MD PhD
-
Effectiveness of sirolimus in severe refractory chronic spontaneous urticaria J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-27 Gaytri Patel MD, David A. Khan MD
-
Accuracy of spring pollen forecasts in five U.S. cities using National Allergy Bureau reporting as a gold standard J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-27 Divya Shah MD, Linda Ford MD, Sergei Ochkur PhD, Susan Kosisky BS MHA, Stanley Fineman MD, Frank Virant MD, Matthew Rank MD
-
Clinical and histologic remission achieved with upadacitinib in a patient with refractory eosinophilic gastritis and duodenitis J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-27 Jerry Fu BS, Twan Sia BA, Rachel Solecki BS, Shibani Mallik BS, Raisa Khuda BS, Madison Headen BS, Leeon Bacchus BA, Michelle Zheng BS, Tanvi Telukunta BS, Saad Shami BS, Stanley Liu BS, Sripad Sureshbabu BS, Kathleen Love BS, Alyssa Roby BS, Paige McDonald BA, Yuting Jiang BS, Dharaneswari Hari Narayanan MBBS, Evan Cunningham BS, Sara Matmatte MD, Puay Eng Tan MD, John Leung MD
There are currently no FDA-approved medications for eosinophilic gastritis and duodenitis. We present a novel case of a patient with eosinophilic gastritis and duodenitis who achieved histologic and symptomatic remission with upadacitinib, a Janus Kinase-1 (JAK1) inhibitor.
-
The Prevalence Of Osteoporosis Is Low In Adult Cutaneous Mastocytosis Patients J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-27 Yannick Degboé MD PhD, Maella Severino-Freire MD, Guillaume Couture MD, Pol-André Apoil MD PhD, Nicolas Gaudenzio PhD, Olivier Hermine MD PhD, Adeline Ruyssen-Witrand MD PhD, Carle Paul MD PhD, Michel Laroche MD, Arnaud Constantin MD PhD, Cristina Bulai Livideanu MD
Systemic mastocytosis (SM) is a clonal disorder of mast cells (MCs) frequently associated with vertebral osteoporosis (OP) and subsequent vertebral fractures (VFs). The natural history of this OP remains unclear. Importantly, we do not know whether OP represents an early event triggered alongside MC abnormalities, and whether MC clonality is sufficient to trigger osteoporosis. To describe OP in patients
-
Respiratory Diseases Associated With Organic Dust Exposure J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-27 Jill A. Poole MD, Jose L. Zamora-Sifuentes DO, Leticia De Las Vecillas MD PhD, Santiago Quirce MD PhD
Organic dusts are complex bioaerosol mixtures comprised of dust and particulate matter of organic origin. These include components from bacteria, fungi, pollen, and viruses to fragments of animals and plants commonplace to several environmental/occupational settings encompassing agriculture/farming, grain processing, waste/recycling, textile, cotton, woodworking, bird breeding, and more. Organic dust
-
Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-27 Taha Al-Shaikhly MBChB, Matthew R. Norris MD, Emily H. Dennis MS, Guodong Liu PhD, Timothy J. Craig DO
Biologic modifiers targeting type 2 (T2) airway inflammation are effective in reducing asthma exacerbation. However, real-world and comparative effectiveness studies remain limited. To examine and compare the real-world impact of anti-T2 asthma biologics. In this retrospective, new user cohort study, we used the MarketScan, a Commercial Claims and Encounters Database, to identify adult patients with
-
Safety and Effectiveness of bypassing oral immunotherapy buildup with an initial phase of sublingual immunotherapy for higher-risk food allergy J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-27 Lianne Soller, Brock A. Williams, Raymond Mak, Tiffany Wong, Stephanie C. Erdle, Alanna Chomyn, Brittany Tetreault, Kelly Morrison, Lisa Gaudet, Edmond S. Chan
Due to its favourable safety, sublingual immunotherapy (SLIT) for food allergy has been proposed as an alternative treatment for those in whom oral immunotherapy (OIT) is higher-risk – older children, adolescents, adults, and those with a history of severe reactions. Although safe, SLIT has been shown to be less effective than OIT. To describe the safety of multi-food SLIT in pediatric patients aged
-
An Ethical Framework for Allergy and Immunology J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-21 Timothy M. Buckey MD MBE, Scott F. Feldman MD PhD, Andrea J. Apter MD MA MS
Ethical dilemmas routinely occur in the clinical practice of allergy and immunology. These ethical questions stem from the range of conditions and the different populations cared for by Allergists/Immunologists. Hence, medical ethics is not an esoteric concept, but a practical skill physicians exercise regularly. Moreover, an ethics-centered approach may improve patient safety and outcomes. This article
-
Validation of the NUT CRACKER Diagnostic Algorithm and Prediction for Cashew and Pistachio Co-Allergy J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-20 Michael R. Goldberg MD PhD, Michael Y. Appel PhD, Katz Tobi, Michael B. Levy MD, Naama Epstein-Rigbi MD, Maria Holmqvist PhD, Jonas Östling PhD, Liat Nachshon MD, Jonas Lidholm PhD, Arnon Elizur MD
Because of the high cross-sensitization among tree nuts, the NUT CRACKER (Nut Co-reactivity-Acquiring Knowledge for Elimination Recommendations) study proposed a diagnostic algorithm to minimize the number of required oral food challenges (OFCs). To validate the algorithm for cashew and pistachio allergy and determine markers for allergic severity. Patients (n = 125) with a median age of 7.9 (interquartile
-
Uncovering Severe Patient Group With Pollen-Related Extrarespiratory Allergic Symptoms: A Year-Long Diary Survey in Japan J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-19 Yuma Fukutomi MD, Hiroshi Tanaka MD, Kiyoshi Sekiya MD, Kentaro Watai MD, Yuto Hamada MD, Maki Iwata MD, Akemi Saito BSc, Koki Okabe MD, Akiko Sugiyama MD, Takehito Fukushima MD, Chie Oshikawa MD, Hideyuki Uetake MEng, Hajime Yoshisue PhD, Takashi Irie MD, Reiko Kishikawa MD
The most common symptoms of pollen allergy are rhinitis and conjunctivitis. However, in real-world clinical practice, we sometimes encounter patients with pollen allergy suffering from severe extrarespiratory symptoms including skin, gastrointestinal, or flu-like symptoms in relation to exposure to sensitized pollen. To elucidate the extrarespiratory symptoms in patients with pollen allergy. We performed
-
Association Between Early Patient Characteristics and IgE-Mediated Allergy in the Perioperative Setting J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-18 Pascale Dewachter MD PhD, Claudie Mouton-Faivre MD, Solohaja Faniaha Dimby PhD, Eric Vicaut MD PhD, Sadek Beloucif MD PhD
Early recognition of perioperative anaphylaxis, a life-threatening, usually IgE-mediated, immediate hypersensitivity, is essential, but bedside diagnosis is not always straightforward because clinical presentation may vary. To describe early characteristics of perioperative immediate hypersensitivity, with special attention to cutaneous phenotypes, and identify risk factors for IgE-mediated allergy
-
Enhancing Patient-Reported Outcome Measures for Drug Hypersensitivity: A Validated 6-Item Quality-of-Life Questionnaire for Patients With Drug Hypersensitivity J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-18 Hugo W.F. Mak MBBS, Valerie Chiang MBBS, Sophia W.M. So MBBS, Jane C.Y. Wong MBBS, Dorothy L.Y. Lam MSc, Elaine Lee MSc, Jackie S.H. Yim MSc, Antonio Romano MD, Philip H. Li MD
Drug hypersensitivity reactions (DHRs) can significantly impair patients’ health-related quality of life (HRQoL). However, tools for HRQoL assessment for patients with DHR are time-consuming and remain underutilized. To develop and validate an optimized version of the Drug Hypersensitivity Quality-of-Life Questionnaire (DrHy-Q) designed for everyday clinical use. Item response theory (IRT), a statistical
-
Environmental Injustice Is Associated With Poorer Asthma Outcomes in School-Age Children With Asthma in Metropolitan Atlanta, Georgia J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-18 Jocelyn R. Grunwell MD PhD, Abby D. Mutic PhD RN, Idil D. Ezhuthachan MD, Carrie Mason BS RRT, Mallory Tidwell BSN RN, Cherish Caldwell RN MPH, Jalicae Norwood BS MPH, Sydney Zack BSN RN, Natalie Jordan MPH, Anne M. Fitzpatrick PhD RN
Environmental justice mandates that no person suffers disproportionately from environmental exposures. The Environmental Justice Index (EJI) provides an estimate of the environmental burden for each census tract but has not yet been used in asthma populations. We hypothesized that children from census tracts with high environmental injustice determined by the EJI would have a greater burden of asthma
-
Anifrolumab to treat a monogenic interferonopathy J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-17 Mohammad-Ali Doroudchi MD, Timothy J. Thauland PhD, Bhavita A. Patel MD, Manish J. Butte MD PhD
-
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-14 Jonathan Corren MD, Stanley J. Szefler MD, Ellen Sher MD, Phillip Korenblat MD, Weily Soong MD, Nicola A. Hanania MD, Gary Berman MD, Guy Brusselle MD PhD, Ralph Zitnik MD, Chitra R. Natalie MD, Luna Sun PhD, Kimberly Siu MD MPH, Wen-Shuo Wu MD, Peter Lio MD, April W. Armstrong MD MPH
LAVOLTA (L)I, LII, and ACOUSTICS were randomized, placebo-controlled, Phase 3 trials of lebrikizumab, a monoclonal antibody targeting IL-13 in patients with uncontrolled asthma. Failure to demonstrate efficacy may have been related to patient selection in those trials. To assess the efficacy in a well-defined subpopulation of patients with elevated blood eosinophil counts and a minimum number of prior
-
Vitamin D primary prevention of respiratory infections and asthma in early childhood: evidence and mechanisms J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-14 Nicklas Brustad, Bo Chawes
Respiratory infections are a leading cause of child morbidity worldwide and asthma is the most common chronic disorder in childhood. Both conditions associate with high socioeconomic costs and are major reasons for medication prescriptions and hospitalizations in children. Vitamin D deficiency has concomitantly increased with asthma prevalence and is hypothesized to play a key role in the development
-
Working With Surgeons Who Provide Endoscopy in Underserved Areas for the Management of Eosinophilic Esophagitis J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-13 Gilbert T. Chua MBBS FHKAM(Paed), Arun Dhir MD, Scott B. Cameron MD PhD, Vishal Avinashi MD, Stephanie C. Erdle MD, Raymond Mak MD, Hin Hin Ko MD, Edmond S. Chan MD
-
Systemic Inflammation in Asthma: What Are the Risks and Impacts Outside the Airway? J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-12 Matthew C. Tattersall DO MS, Nizar N. Jarjour MD, Paula J. Busse MD
Airway inflammation in asthma has been well recognized for several decades, with general agreement on its role in asthma pathogenesis, symptoms, propensity toward exacerbation, and decline in lung function. This has led to universal recommendation in asthma management guidelines to incorporate the use of inhaled corticosteroid as an anti-inflammatory therapy for all patients with persistent asthma
-
Budesonide/formoterol or budesonide/albuterol as anti-inflammatory reliever therapy for asthma J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-10 Brian Lipworth, Chris RuiWen Kuo, Kirsten Stewart, Rory Chan
Over use of reliever as short acting beta-agonist (SABA) and associated underuse of controller as inhaled corticosteroid (ICS) administered via separate inhalers results in worse asthma outcomes . Such discordance can be obviated by combining both controller and reliever in the same inhaler. So called anti-inflammatory reliever (AIR) therapy comprises the use of a single inhaler containing an ICS such
-
Theme Editorial: Asthma Updates: Theories Translated to Treatment J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-10 William Busse, Mario Castro
-
The Relationship Between Allergic Rhinitis, Asthma, and Cardiovascular Disease in the National Health Interview Surveys (NHIS), 1999–2018 J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-08 Sairaman Nagarajan MD MPH, Janet Rosenbaum PhD, Rauno Joks MD FAAAAI
Atopic disease has been associated with immune dysregulation and chronic inflammation, but current practice guideline recommendations do not include the evaluation of inflammatory outcomes among patients with asthma and allergic rhinitis (AR). This study investigates the relationship between asthma, AR, and cardiovascular disease (CVD) using data from the U.S. National Health Interview Survey (NHIS)
-
Reply to “Diet may be the common factor linking aspirin-exacerbated respiratory disease and atherosclerotic cardiovascular disease” J. Allergy Clin. Immunol. Pract. (IF 9.4) Pub Date : 2024-02-07 Michael J. Adame, Mukaila Raji, Yong Shan, Yuanyi Zhang, Yong-Fang Kuo, Julia W. Tripple